Masimo price target raised to $145 from $125 at BTIG

BTIG raised the firm’s price target on Masimo to $145 from $125 and keeps a Buy rating on the shares. The firm’s recent discussions with the management left it with an impression that the recent slowdown in the health care business is now behind the company and that Masimo is back on the right path to achieve consistent and predictable growth, the analyst tells investors in a research note. Masimo management also emphasized customer ordering patterns over the last six months and that hospital census have normalized, providing greater visibility to set “high-conviction” guidance for 2024, the firm added.